Early Stage HER2+ Breast Cancer trials recruiting in District of Columbia

Fewer than 3 recruiting trials found.

All Early Stage HER2+ Breast Cancer trials nationally

Cities in District of Columbia

Recruiting trials in District of Columbia

• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
  NCT06876714 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · District of Columbia: Washington D.C.